Advances in the clinical translation of nanotechnology.

TitleAdvances in the clinical translation of nanotechnology.
Publication TypeJournal Article
Year of Publication2017
AuthorsScheinberg DA, Grimm J, Heller DA, Stater EP, Bradbury M, McDevitt MR
JournalCurr Opin Biotechnol
Volume46
Pagination66-73
Date Published2017 Aug
ISSN1879-0429
KeywordsDiagnostic Imaging, Genetic Therapy, Humans, Nanostructures, Nanotechnology, Neoplasms, Translational Research, Biomedical
Abstract

The use of novel materials in the nano-scale size range for applications in devices, drugs and diagnostic agents comes with a number of new opportunities, and also serious challenges to human applications. The larger size of particulate-based agents, as compared to traditional drugs, allows for the significant advantages of multivalency and multi-functionality. However, the human use of nanomaterials requires a thorough understanding of the biocompatibility of the synthetic molecules and their complex pharmacology. Possible toxicities created by the unusual properties of the nanoparticles are neither well-understood, nor predictable yet. A key to the successful use of the burgeoning field of nanomaterials as diagnostic and therapeutic agents will be to appropriately match the biophysical features of the particle to the disease system to be evaluated or treated.

DOI10.1016/j.copbio.2017.01.002
Alternate JournalCurr Opin Biotechnol
PubMed ID28187340
PubMed Central IDPMC5544552
Grant ListDP2 HD075698 / HD / NICHD NIH HHS / United States
R01 CA055349 / CA / NCI NIH HHS / United States
P01 CA033049 / CA / NCI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
U54 CA199081 / CA / NCI NIH HHS / United States
R01 CA161280 / CA / NCI NIH HHS / United States